SAB Biotherapeutics (NASDAQ:SABS) Trading Up 0.6% - Still a Buy?

Key Points

• SAB Biotherapeutics shares edged up 0.6% on Wednesday, trading between $3.60 and $3.67 on lighter-than-average volume.
• Analyst sentiment remains mostly positive, with nine Buy ratings and a consensus price target of $12.00, though one firm still rates it a Sell.
• The company reported a wider-than-expected quarterly loss, posting EPS of -$0.35 versus the expected -$0.20, and analysts forecast a full-year loss of -$1.19 per share.

SAB Biotherapeutics, Inc. (NASDAQ:SABS - Get Free Report)'s stock price shot up 0.6% during mid-day trading on Wednesday . The company traded as high as $3.67 and last traded at $3.62. Approximately 368,862 shares changed hands during trading, a decline of 56% from the average daily volume of 835,619 shares. The stock had previously closed at $3.60.

Wall Street Analyst Weigh In

SABS has been the subject of several research reports. Leerink Partners raised their price objective on shares of SAB Biotherapeutics from $7.00 to $12.00 and gave the company an "outperform" rating in a research report on Monday, June 15th. Weiss Ratings reissued a "sell (d+)" rating on shares of SAB Biotherapeutics in a research note on Wednesday, July 8th. HC Wainwright restated a "buy" rating and set a $10.00 target price on shares of SAB Biotherapeutics in a report on Monday, June 15th. Zacks Research upgraded shares of SAB Biotherapeutics from a "strong sell" rating to a "hold" rating in a research report on Monday, May 11th. Finally, Rodman & Renshaw reaffirmed a "buy" rating and issued a $13.00 price target on shares of SAB Biotherapeutics in a report on Monday, May 11th. Nine research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $12.00.

SAB Biotherapeutics Stock Performance

The firm's fifty day simple moving average is $3.73 and its 200 day simple moving average is $3.85. The company has a market capitalization of $276.79 million, a price-to-earnings ratio of -1.72 and a beta of 0.52. The company has a debt-to-equity ratio of 0.01, a current ratio of 11.45 and a quick ratio of 11.45.

SAB Biotherapeutics (NASDAQ:SABS - Get Free Report) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.15). On average, sell-side analysts forecast that SAB Biotherapeutics, Inc. will post -1.19 EPS for the current year.

Institutional Trading of SAB Biotherapeutics

Several large investors have recently added to or reduced their stakes in SABS. PNC Financial Services Group Inc. acquired a new stake in shares of SAB Biotherapeutics in the first quarter worth $29,000. State of Wyoming purchased a new stake in SAB Biotherapeutics in the 4th quarter worth about $34,000. State Street Corp acquired a new stake in SAB Biotherapeutics during the 4th quarter worth about $49,000. Fifth Lane Capital LP acquired a new stake in SAB Biotherapeutics during the 4th quarter worth about $56,000. Finally, ADAR1 Capital Management LLC purchased a new position in SAB Biotherapeutics during the 3rd quarter valued at about $30,000. 7.82% of the stock is owned by institutional investors and hedge funds.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company's proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company's lead programs are directed primarily at infectious diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.